Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 3
2023 pubmed

ApoE Mimetic Peptide COG1410 Exhibits Strong Additive Interaction with Antibiotics Against <i>Mycobacterium smegmatis</i>.

Zhao. Yan-Yan YY; Wang. Chun C; Wang. Wei-Xiao WX; Han. Li-Mei LM; Zhang. Caiyun C; Yu. Jiao-Yang JY; Chen. Wei W; Hu. Chun-Mei CM

Key Findings

  • COG1410 kills M. smegmatis in vitro with an MIC of 16 µg/mL, comparable to clarithromycin and faster than LL‑37
  • It disrupts bacterial membranes, reduces biofilm formation by ~90%, and can act inside macrophages
  • Shows additive (non‑antagonistic) interaction with standard anti‑TB antibiotics and no resistance after 30 passages, but has relatively high cytotoxicity

Practical Outcomes

  • COG1410 isn’t a practical supplement for biohackers now—its toxicity and lack of activity against actual TB strains limit safe self‑use. However, the study highlights that membrane‑targeting peptides can boost antibiotics and may guide future low‑dose combination approaches once safety is improved.

Summary

The peptide COG1410 can kill a lab strain of mycobacteria (M. smegmatis) at a modest dose, works by breaking the bacterial membrane, reduces biofilm, and helps antibiotics work better, but it’s also fairly toxic to human cells and doesn’t affect the real TB bacteria, so it’s not ready for personal use yet.

Abstract

Drug-resistant tuberculosis (TB) is an emerging threat to public health worldwide. Antimicrobial peptide (AMP) is a promising solution to solve the antimicrobial resistance crisis. The apolipoprotein E mimetic peptide COG1410 has been confirmed to simultaneously have neuroprotective, anti-inflammatory, and antibacterial activity. However, whether it is effective to inhibit growth of mycobacteria has not been investigated yet. The peptide COG1410 was synthesized with conventional solid-phase peptide synthesis and qualified by HPLC and mass spectrometry. Micro-dilution method was used to determine the minimal inhibitory concentration. A time-kill assay was used to determine the bactericidal dynamics of antimicrobial peptide and relative antibiotics. Static biofilm formation was conducted in 24-well plate and the biofilm was separated from planktonic cells and collected. The mechanism of action of COG1410 was explored by TEM observation and ATP leak assay. The localization of COG1410 was observed by confocal laser scan microscopy. The drug-drug interaction was determined by a checkerboard assay. COG1410 was a potent bactericidal agent against <i>M. smegmatis</i> in vitro and within the macrophages with MIC 16 &#x3bc;g/mL, but invalid against <i>M. abscess</i> and <i>M. tuberculosis</i>. A time-kill assay showed that COG1410 killed <i>M. smegmatis</i> as potent as clarithromycin, but faster than LL-37, another short synthetic cationic peptide. 1&#xd7; MIC COG1410 almost reduced 90% biofilm formation of <i>M. smegmatis</i>. Additionally, COG1410 was able to penetrate the cell membrane of macrophage and inhibit intracellular <i>M. smegmatis</i> growth. TEM observation and ATP leak assay found that COG1410 disrupted cell membrane and caused release of cell contents. Confocal fluorescence microscopy showed that FITC-COG1410 aggregated around cell membrane instead of entering the cytoplasm. Although COG1410 had relative high cytotoxicity, it exhibited strong additive interaction with regular anti-TB antibiotics, which reduced the working concentration of COG1410 and expanding safety window. After 30 passages, there was no induced drug resistance for COG1410. COG1410 was a novel and potent AMP against <i>M. smegmatis</i> by disrupting the integrity of cell membrane.

Study Information

Provider

pubmed

Year

2023

Date

2023-03-28T00:00:00.000Z

DOI

10.2147/idr.s403232